Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) are widely recognized for their roles in ovulation and the support of early pregnancy. Aside from the timing of expression, however, the differences between LH and hCG have largely been overlooked in the clinical realm because of their similar molecular structures and shared receptor. With technologic advancements, including the development of highly purified and recombinant gonadotropins, researchers now appreciate that these hormones are not as interchangeable as once believed. Although they bind to a common receptor, emerging evidence suggests that LH and hCG have disparate effects on downstream signaling cascades. Increased understanding of the inherent differences between LH and hCG will foster more effective diagnostic and prognostic assays for use in a variety of clinical contexts and support the individualization of treatment strategies for conditions such as infertility.
Introduction
It is well established that luteinizing hormone (LH) and human chorionic gonadotropin (hCG) play key roles in the reproductive cycle. Textbooks recognize the disparate endogenous functions of these hormones, underscoring the role of LH in follicular maturation and ovulation induction, while acknowledging the essential role of hCG in early pregnancy survival. During early pregnancy, hCG is vital to support secretion of progesterone by the corpus luteum, without which a pregnancy cannot persist (Fritz and Speroff, 2011; Mesiano, 2009) . Nonetheless, LH and hCG are frequently depicted as interchangeable, with one contemporary text stating that the 'b subunits [of human LH (hLH) and hCG] confer identical biologic activities when associated with the a subunit' (Bulun, 2011) .
Although similar in structure and function, LH and hCG are distinct molecular entities with divergent patterns of expression and physiologic functions. LH and hCG share a common receptor, yet each hormone triggers a unique cascade of events following receptor binding (Casarini et al., 2012; Gupta et al., 2012) . Moreover, within the same hormone family, individual isoforms exhibit unique characteristics regarding half-life and biologic functions. Emerging data suggest that these differences between LH and hCG have functional significance. Identifying the unique roles of LH and hCG is key to understanding both normal physiologic processes (e.g., reproduction, placentation) and dysfunctional states (e.g., infertility, gestational and non-gestational neoplasms). Advances in gonadotropin purification and recombinant technology have helped to differentiate the varied actions of LH and hCG. In turn, this has improved the diagnosis and treatment of human disease, most significantly in the context of infertility.
Materials and methods
A comprehensive literature review of LH and hCG was conducted, focusing on differentiation in terms of hormone structure, expression, modification, receptor activation, and clinical use. Scientific literature was identified via interrogation of the MEDLINE database using relevant search terms, including but not limited to: 'gonadotropin', 'human chorionic gonadotropin', 'luteinizing hormone', 'luteinizing hormone/choriogonadotropin receptor', 'lutropin', and 'lutropin receptor'. Results were limited to articles published in English. Additional resources were extracted from clinical texts and review articles. Article inclusion was predicated on relevance to the topic without use of an objective set of criteria, given that the review is descriptive rather than systematic in nature.
Molecular structure
Both LH and chorionic gonadotropin (CG) are heterodimeric glycoproteins comprised of a and b subunits. Along with thyroidstimulating hormone (TSH) and follicle-stimulating hormone (FSH), they share a common 92-amino acid a subunit, whose gene resides on chromosome 6q12-q21 in humans (Bulun, 2011; Naylor et al., 1983) . The unique functions and receptor-binding capacity of each of these hormones stem from differences among the b subunits (Table 1) . Transcription of the b-subunit is the rate-limiting step in LH and CG production (Nagirnaja et al., 2010) . The genes for the LH and hCG b subunits are located within a cluster of seven similar sequences on human chromosome 19q13.32 (Boorstein et al., 1982; Jameson and Hollenberg, 1993) . One of those sequences encodes the b-subunit of LH (LHB); four are hCG b-subunit coding genes (CGB, CGB5, CGB7, and CGB8), and the remaining two are pseudogenes (CGB1, CGB2).
The high degree of sequence conservation among CGB genes, combined with the fact that CG is detected only in equine and primate species (whereas LH is found in all vertebrates) suggests that CG is a relatively recent evolutionary derivative of LH. The amino acid sequences of human LH (hLH) and hCG are highly conserved, sharing 82% homology (Bulun, 2011) . hCG retains the full 145Àamino-acid complement in its b-subunit. In contrast, the b-subunit of LH undergoes cleavage of its 24-amino acid leader sequence to generate its final 121-amino acid sequence.
As a result of structural differences and post-translational modifications, hCG is more stable and has a longer circulating half-life than LH. The half-lives of these molecules typically are expressed as a range (on the order of minutes for LH and hours for hCG), reflecting the heterogeneity of circulating isoforms. The shorter half-life of LH is physiologically important, as it allows for the production of LH pulses. The longer half-life of hCG and its greater receptor binding affinity make it more biologically active than hLH (Rahman and Rao, 2009; Rao, 1979) .
Gonadotropin variants
In the endogenous state, LH and hCG consists of isohormone mixtures that result from (1) post-translational modification of the native proteins; (2) metabolism to form truncated or nicked intermediates; and (3) natural sequence variants (Bergendah and Veldhuis, 2001; Cole, 2009; Stanton et al., 1993) . Post-translational modification chiefly consists of the addition of various carbohydrate side chains, including sialic and sulfonic acid moieties, thus creating a variety of isoforms (upwards of 30 for LH and 15 for hCG) that differ with respect to half-life, bioactivity, and signaling properties (Arey and Lopez, 2011; Bergendah and Veldhuis, 2001; Cole, 2009; Stanton et al., 1993) . Obviously, the number of isoform classes for each hormone is determined by our capacity for analytical discrimination. Because glycosylation affects the size and conformation of the molecule as well as access to binding sites, differences in interactions with their cognate receptor are to be expected (Arey and Lopez, 2011) .
Naturally occurring variants of both LH and hCG have been characterized. A variant of LH that has an additional glycosylation site compared with wild-type LH is relatively common within certain populations (Lamminen and Huhtaniemi, 2001; Nilsson et al., 1997) . Data have been collected showing that variant LH differs from normal LH in its biological effects (Haavisto et al., 1995) . This LH variant has been associated with unexplained infertility and subfertility due to ovulatory dysfunction in females, and with slowed pubertal progression in males (Raivio et al., 1996; Takahashi et al., 1998 Takahashi et al., , 1999 . Preliminary data also suggest that the variant LH is more prevalent among women who demonstrate resistance to ovarian stimulation with recombinant human FSH, compared with those who exhibit moderate or strong responses (Alviggi et al., 2011) . Men with one or two copies of the variant allele have lower circulating LH levels compared with homozygotes for the wild-type allele (Huhtaniemi et al., 2010) . However, the ratio of biological-to-immunological activity (a measure of relative LH biopotency) for variant LH is greater than that of wild-type LH (Haavisto et al., 1995) . A less common LH variant resulting in a single amino acid substitution in the b subunit (serine for glycine at amino acid 102) has been associated with menstrual disorders and male infertility (Hashad et al., 2012; Ramanujam et al., 1999 Ramanujam et al., , 2000 . Little is known about how this rare variant affects the functionality of LH. Based on in vivo experiments, Wide et. al. showed that an extra glycosylation site on variant LH compared to the wild type, allows for greater sialylation and results in a longer half-life in serum. Granulosa cells are triggered typically by distinct pulses of LH; however, because of its prolonged residence in serum, granulosa cells are exposed to decreased pulse amplitudes of variant LH. Thus, Wide, et. al. proposed that the longer half-life of variant LH may be a contributing factor to the reproductive disorders observed (Wide et al., 2010) .
Although hCG polymorphisms with functional significance are generally rare, variants in the b subunit of hCG with putative protective or detrimental effects on recurrent miscarriage risk have been identified (Nagirnaja et al., 2012; Rull et al., 2008) . The sequence changes associated with increased risk of recurrent miscarriage occur in the most commonly transcribed hCG b-subunit genes, CGB5 and CGB8, and result in conformational changes to the protein's structure (Nagirnaja et al., 2012) . One of the b-subunit missense mutations in particular-hCG b p.Val56Leu adversely impacts its ability to bind efficiently with its a-subunit with only 10% forming the complete hCG heterodimer. However, additional studies show increased bioactivity of this resultant variant hCG (possibly due to subtle conformational changes) when bound to LHCGR, increasing the impact of this more sparsely produced variant hCG. The paucity of polymorphisms that have been identified in hCG imply that only modest changes in CGB5 and CGB8 are compatible with a successful pregnancy outcome.
Circulating forms

Luteinizing hormone
Gonadotrophic cells of the anterior pituitary produce LH, which regulates ovulation. Over the course of a normal menstrual cycle, a surge in LH spurs ovulation from the dominant follicle. This process initiates during the mid-follicular phase, when LH stimulates androgen production in thecal cells. These androgens are aromatized in the granulosa cells to estrogen. Prolonged, sustained estrogen levels generate positive feedback on the pituitary gland and the subsequent LH surge that results in ovulation (Liu and Yen, 1983) Post-ovulation, LH promotes progesterone production, supporting development of the corpus luteum (Van de Wiele et al., 1970) .
The composition of LH isoforms, their longevity, and their bioactivity vary throughout the menstrual cycle. The ratio of biological-to-immunological activity is lowest during the luteal phase, rising slowly during the follicular phase to a peak at mid-cycle . This corresponds with the pinnacle of LH sialylation and a marked trough in sulfonation (Wide and Eriksson, 2013) . Earlier studies had established that sialylation prolongs LH half-life, whereas sulfonation hastens protein elimination (Burgon et al., 1996; Wide et al., 2009) . Changes in the extent of glycosylation during the menstrual cycle appear to be regulated by the pituitary gland, under the influence of such factors as gonadotropin-releasing hormone (GnRH), estradiol, and testosterone (Bergendah and Veldhuis, 2001; Lambert et al., 1998; Wide and Bakos, 1993) .
Variations in LH isoform composition are also observed during the reproductive life cycle. In general, LH isoforms with shorter half-lives but increased biopotency are present in younger postpubertal women, whereas longer-lived LH species are the predominant form detected in post-menopausal women (Reader et al., 1983; Wide, 1985) . LH in the latter group also has an increased ratio of biological-to-immunological activity (Marrama et al., 1983) . Interestingly, women with polycystic ovarian syndrome (PCOS)-an endocrine condition associated with reduced fertility-appear to predominantly secrete LH isoforms that have a high ratio of biological-to-immunological activity (Ding and Huhtaniemi, 1991; Ropelato et al., 1999) . Molecular analysis of LH in women with PCOS has revealed a substantial decrease in sulfonation at midcycle, accompanied by a slight increase in sialylation compared with non-affected individuals (Wide et al., 2007) . The net result is an increase in basic LH isoforms relative to women without PCOS (Ropelato et al., 1999; Wide et al., 2007) . It is unclear what influence, if any, these changes have on the half-life of LH. It is known that that basic LH isoforms are, in general, cleared more rapidly than acidic isoforms, yet based on findings regarding the specific effects of sialylation vs. sulfonation on LH half-life (Burgon et al., 1996; Wide et al., 2009) , the changes observed in women with PCOS would be expected to increase LH residence time in circulation. This question is made more complex by the apparent effect of body mass index (BMI) on the LH profile of women with PCOS (Srouji et al., 2007) . Current dogma posits that increased basal secretion of LH plays a greater role than altered post-translational modification in the elevated serum LH concentrations that have been observed among women with PCOS.
In men, LH stimulates testosterone production by Leydig cells of the testis. The degree of LH sialylation and the ratio of biologicalto-immunological activity of LH are generally greater in men than in pre-menopausal women (Bergendah and Veldhuis, 2001; Wide et al., 2007) . Unlike women, however, the biological-to-immunological activity ratio of LH decreases with age in men (Marrama et al., 1984; Warner et al., 1985) . A shift toward more LH species that have a shorter serum half-life has been described in obese men, which may be a source of the reduced testosterone levels reported in those individuals (Castro-Fernandez et al., 2000) .
Human chorionic gonadotropin
At least four physiologically important isoforms of hCG have been described, including regular hCG, hyperglycosylated hCG (hhCG), hyperglycosylated free hCG b subunit, and pituitary hCG. Different cell types produce these isoforms, which have unique, although sometimes overlapping, functions. Each of the four variants shares a common protein sequence (at least for the b subunit), but each is modified differently, resulting in isoforms with disparate half-lives and biologic functions. The distribution and quantity of hCG isoforms varies over the course of pregnancy and in the context of aberrant development or disease. For example, in early pregnancy, an abnormally low proportion of h-hCG to total hCG (<50%) indicates a failing pregnancy, (Kovalevskaya et al., 2002; Sasaki et al., 2008) , while decreased first trimester serum free bhCG levels have been associated with ectopic pregnancies (Borrelli et al., 2003) . Conversely, elevated h-hCG can indicate choriocarcinoma or Down syndrome pregnancy (Cole et al., 1999; Elliott et al., 1997; Palomaki et al., 2007) .
Regular hCG is secreted by fused and differentiated syncytiotrophoblasts. It is the predominant hCG species measured in serum during pregnancy, after the initial early surge of h-hCG (Cole, 2010) . The chief role of hCG historically has been the promotion of progesterone secretion by the corpus luteum in early pregnancy. However, as noted by Cole, hCG levels continue to increase after hCG is no longer needed for progesterone production, suggesting other functions for this hormone during pregnancy (Cole, 2009) .
It is now believed that hCG is involved in placentation through activities such as maintaining angiogenesis of the uterine vasculature and promoting differentiation of cytotrophoblasts into syncytiotrophoblasts (Rao and Alsip, 2001; Shi et al., 1993; Zygmunt et al., 2002) . Emerging evidence also suggests roles for regular hCG in fostering implantation, preventing fetal rejection, coordinating uterine and fetal growth, and, potentially, growth and development of fetal organs (Cole, 2010) . The varieties of established and putative functions for regular hCG are listed in Table 2 .
Secreted by root or extravillous cytotrophoblasts, h-hCG concentrations peak early in the first trimester. The percentage of hCG in the form of h-hCG subsequently declines, becoming a minor component of total hCG measurement during the last two trimesters. The key differentiator between regular hCG and h-hCG is the complexity of the oligosaccharide side chains: h-hCG tends toward oligosaccharides with a greater number of sugar residues. Consequently, the molecular weight of h-hCG is in the range of 40,000-41,000 Da, whereas that of regular hCG is approximately 36,000 Da. The additional sugar moieties prevent normal protein folding, thus exposing alternative receptor binding sites and altering the hormone's functionality (Cole, 2010) . Indeed, results of recent experiments by Berndt and colleagues indicate that h-hCGmediated angiogenesis may occur independent of activation of its cognate receptor (Berndt et al., 2013) .
The association between pregnancy loss and low h-hCG levels supports a key role for this variant in implantation (Kovalevskaya et al., 2002; Sasaki et al., 2008) . The importance of h-hCG in implantation/invasion is also evident in the context of choriocarcinoma, as a pathologic process (Cole, 2010) . Current data suggest that h-hCG and hCG act in conjunction to forewarn the endometrium of impending implantation, to foster growth and differentiation of trophoblast cells, and to establish placental villous structures.
During pregnancy, the amount of total and h-hCG in serum and urine demonstrates a high degree of inter-individual variability (Cole, 2010) . This endogenous variation may be normalized at the receptor level via downregulation in the presence of high hCG concentrations, or through the 'spare receptor' concept, which generates the same response regardless of the proportion of receptors activated. The end result is that, unless the hCG level is insufficient to support its basic functionality, variation is compatible with normal pregnancy.
Hyperglycosylated free hCG b subunits are found at low levels during normal pregnancy and are also produced by non-trophoblastic malignancies (Butler et al., 2000; Cole, 2009; Cole et al., 1988; Iles et al., 1990) . Akin to h-hCG, the hyperglycosylated free b subunit is characterized by N-and O-linked oligosaccharides containing a large number of sugar residues. Free b subunits are not only a biomarker of malignancy but are also believed to play an active role in cancer development by preventing apoptosis and promoting carcinogenesis (Butler et al., 2000; Cole and Butler, 2008) . Indeed, elevated levels of free b-hCG in urine samples of patients with malignancies increase the likelihood for metastasis and mortality (Butler et al., 2000; Iles et al., 1996) . The anti-apoptotic effects of free b-hCG may result from antagonistic inhibition of other growth factor receptors, rather than interaction with the canonical receptor (Butler and Iles, 2004) . Because it lacks the a subunit, free b-hCG cannot bind to the lutropin receptor (Cole, 2009) .
Pituitary hCG is secreted by gonadotrophic cells of the anterior pituitary. The higher number of sulfonated side chains of pituitary hCG gives it a shorter half-life than its placental counterpart (Birken et al., 1996) . Pituitary hCG is present in all adults, including men and pre-/post-menopausal women, and is suppressed with GnRH agonist treatment Griffin, 1987, 1989) . During a regular menstrual cycle, pituitary hCG secretion parallels that of LH, although the half-life of pituitary hCG is shorter than that of LH. As much as one-third of follicular-stage LH activity may derive from hCG during a natural menstrual cycle (Cole, 2010) . The function of pituitary hCG is generally not known, but its concomitant temporal appearance with LH during the menstrual cycle and common receptor suggest that its functionality may mimic LH-stimulating follicular maturation, inducing ovulation, and supporting progesterone production during the luteal phase (Cole, 2010) . In contrast, expression of the LHB gene is down-regulated in pregnancy (Rull and Laan, 2005) suggesting that while hCG might have a functional role during the normal menstrual cycle, LH cannot substitute for hCG in supporting pregnancy.
Metabolism
Gonadotropins undergo a series of metabolic conversions before ultimately being excreted in urine (Braunstein, 2011; Cole, 2009; O'Connor et al., 1998) . This process has been well characterized for hCG. One of the initial steps in hCG degradation is proteolytic cleavage of the b subunit (possibly by human leukocyte elastase), which generates a 'nicked' form of the protein. Nicked hCG rapidly dissociates into its component a and b subunits.
(Alternately, hCG that has not been nicked may slowly dissociate prior to enzymatic cleavage.) Therefore, h-hCG dissociates more readily than regular hCG in this context. The nicked b subunit is further degraded, predominantly in the kidneys, resulting in a bcore fragment. A comparable LH b-core fragment has been isolated from human pituitary and urine samples (O'Connor et al., 1998) . Given the array of glycosylated hCG forms and the potential for nicked and dissociated varieties therein, a multitude of hCG degradation products are detected in the urine of pregnant women, of which the b-core fragment is most prevalent from 7 weeks' gestation onward (Cole, 2009 ). In total, more than 30 hLH isoforms and 15 variants of hCG have been identified from serum and urine samples (Cole, 2009; Stanton et al., 1993) .
The extent of gonadotropin glycosylation dictates molecular charge, which, in turn, governs clearance rate, such that more acidic isoforms have a longer half-life in vivo (Lambert et al., 1998) . Investigators have also noted that the sialic acid content of LH positively correlates with metabolic clearance rate (Burgon et al., 1996) . In other words, a greater degree of sialylation increases LH retention in circulation. This observation holds true in the context of GnRH receptor blockade as well. In response to GnRH receptor blockade, LH levels decrease and the overall glycosylation profile shifts: the mean number of sialic acid residues per molecule increases and the number of sulfonated residues decreases (Wide et al., 2009 ). The more sialylated and less sulfonated LH isoforms have longer circulating half-lives. A similar effect occurs naturally via an LH polymorphism that results in an extra site for glycosylation. This LH variant has an increased number of sialic acid residues per molecule, resulting in a circulating half-life approximately 40% longer than wild-type LH in humans (Wide et al., 2010) .
hCG glycosylation also affects its longevity in circulation. Metabolic clearance rates of deglycosylated, b-core fragment, and desialylated hCG are all faster relative to hCG, with the greatest degree of acceleration observed for desialylated hCG (Liu et al., 1989; Rosa et al., 1984) . The effects of naturally occurring hCG polymorphisms on metabolic clearance rate or protein half-life have yet to be described.
As a valuable early marker of pregnancy as well as various disease states, the ability to accurately measure hCG in its myriad forms is particularly important. Beyond pregnancy detection, hCG measurement is useful for identifying gestational trophoblastic disease, risk of failing or abnormal pregnancy, and non-gestational malignancies. The predominant hCG species characteristic of each of these conditions differs. In early pregnancy and gestational trophoblastic disease, h-hCG is the dominant form, whereas elevated free b-subunit production is characteristic of certain cancers (Cole et al., 1988; Elliott et al., 1997; Hoermann et al., 1992; Iles et al., 1990; Mock et al., 2000) . Abnormalities in hhCG are also used to assess pregnancy-related risks-elevated maternal blood levels during the first and second trimester are associated with fetal aneuploidy risk such as Down syndrome while low h-hCG in the latter stages of pregnancy is emerging as a putative marker of preeclampsia risk (Bahado-Singh et al., 2002; Cole, 2009 ).
In the case of both LH and hCG, the multiple circulating forms complicate their measurement in blood and urine (Cole, 2009; O'Connor et al., 1998) . For example, total hCG assays, which are the preferred measurement tool used by clinical laboratories, are effective for quantifying regular hCG, but are generally suboptimal for detecting h-hCG (Cole, 2009) . Moreover, in addition to differences in glycosylation and degradation rates, genetic variants have been found to impede detection of LH by immunoassay (O'Connor et al., 1998; Pettersson and Soderholm, 1991) . Detection limits must also be taken into account when assessing gonadotropin presence or absence in clinical testing. Extremes in gonadotropin concentrations that occur within certain clinical contexts may generate erroneous results. It is important, therefore, to be aware of the limitations for a particular assay when interpreting laboratory findings.
6. Receptor binding 6.1. Luteinizing hormone/choriogonadotropin receptor LH and hCG bind to and activate a common receptor, the LH/ choriogonadotropin receptor (LHCGR), also known as the LH or lutropin receptor (LHR) (Ascoli et al., 2002; Puett et al., 2007) . This 675-amino-acid, G-protein-coupled receptor is a member of the rhodopsin subfamily of glycoprotein hormone receptors, as are the FSH and TSH receptors. Like all G-protein coupled receptors, LHCGR is anchored within the cell membrane by seven transmembrane domains. The unusually large extracellular domain of LHCGR is characterized by leucine-rich repeats and multiple sites for glycosylation (Fig. 1) . The human LHCGR gene is located on chromosome 2p21, in the same general region as the FSH receptor (Rousseau-Merck et al., 1993 .
Consistent with its role in female reproduction, LHCGR is expressed by multiple cell types in the ovary, including thecal, luteal, interstitial, and differentiated granulosa cells (Ascoli et al., 2002) . Expression of LHCGR in these cell types during the ovarian cycle is dynamic rather than constitutive, reflecting changes in the hormonal milieu (Menon and Menon, 2012; Menon et al., 2010) . LHCGR is downregulated transiently after the pre-ovulatory LH surge, reaches a maximum at mid-luteal phase, and decreases with corpus luteum regression. This pattern is the inverse of what has been observed for bioactive LH isoforms, wherein peak biologicto-immunologic activity occurs at midcycle and reaches its lowest point during the luteal phase . The mechanisms that govern temporal changes in LHCGR expression are not yet fully elucidated but are generally believed to involve transcriptional as well as post-transcriptional regulation (Ascoli et al., 2002; Menon and Menon, 2012) . Induction of LHCGR expression in differentiating granulosa cells in response to FSH is an example of predominantly transcriptional control, whereas desensitization of LHCGR in response to LH or hCG exposure includes an element of post-transcriptional regulation. Agonist-mediated desensitization of LHCGR involves a reduction in cell surface receptor concentration, as well as diminished mRNA abundance. The decrease in mRNA has been attributed to increased transcript degradation rather than suppressed transcription (Lu et al., 1993) .
Through a series of studies involving rat and human ovarian models, Menon and colleagues identified a binding protein, mevalonate kinase, which appears to regulate LHCGR expression by hastening degradation of LHCGR mRNA ). An inverse correlation was observed between LHCGR mRNA and mevalonate kinase activity: when one was elevated, the other was decreased (Nair et al., 2002) . Moreover, inhibition of mevalonate kinase prevented downregulation of LHCGR in response to hCG, whereas overexpression of mevalonate kinase ameliorated induction of LHCGR in the presence of FSH and estradiol (Ikeda et al., 2008; Wang et al., 2007) .
Alternative splicing of LHCGR mRNA has been implicated in regulation of the ovarian cycle and luteolysis (Dickinson et al., 2009; Minegishi et al., 2007) . Splice variants differ in exon content and, consequently, in their ability to bind or respond to LH or hCG. Using human corpora lutea obtained at various stages of the ovarian cycle, investigators have demonstrated quantitative, but not qualitative, differences in the profile of LHCGR splice variants, indicating that the relative abundance of mRNA species changes throughout the ovarian cycle but their identity did not (Dickinson et al., 2009; Madhra et al., 2004) .
In vitro evidence suggests that gonadotropin signaling through LHCGR influences the expression of individual splice variants (Dickinson et al., 2009) . Previous experiments had shown that one of the identified LHCGR splice variants forms complexes with LHCGR or the FSH receptor, influencing receptor expression and preventing the latter from reaching the cell surface (Nakamura et al., 2004; Yamashita et al., 2005) . More recently, a truncated form of LHCGR lacking transmembrane or carboxyterminal domains negatively regulated the expression and activity of the full-length protein (Dickinson et al., 2009 ). Further study is needed to elucidate the physiologic significance of LHCGR splice variants.
Frank mutations in LHCGR are associated with developmental and reproductive abnormalities, including psuedohermaphrodism, micropenis, hypospadias, and infertility (Ascoli et al., 2002; Menon and Menon, 2012) . Emerging data also suggest that polymorphisms in the LHCGR sequence contribute to risk for conditions associated with infertility, including PCOS. A genome-wide association study that detected a link between a polymorphic marker in the region of LHCGR and PCOS in Han Chinese women (which was confirmed in a subsequent case-control cohort) spurred several similar investigations in other ethnic groups (Chen et al., 2011; Shi et al., 2012) . The specific polymorphic marker associated with PCOS in the Han Chinese population failed to correlate with PCOS in European populations (Eriksen et al., 2012; Mutharasan et al., 2013) ; however, linkage within the genomic region of LHCGR was maintained upon fine mapping in one study (Mutharasan et al., 2013) .
Utilizing an actual LHCGR sequence variant rather than a neighboring polymorphic marker, Capalbo and colleagues reported a correlation between the 312N LHCGR allele and increased risk for PCOS in women of Sardinian origin (Capalbo et al., 2012) . A dose-dependent effect was observed for this polymorphism, such that homozygosity of the 312N allele was associated with a further elevated risk Le Cotonnec et al. (1998a) b Le Cotonnec et al. (1998b) c Trinchard-Lugan et al. (2002) d Doses used were consistent with ED 50 for r-hLH and for r-hCG in COS-7/LHCGR cells. e COS-7/LHCGR cells constitutively express LHCGR. LHCGR expression in hGLC cells is under physiologic regulation. f 100 pM dose used for both r-hLH and r-hCG (Casarini et al., 2012) . of PCOS beyond that of a single copy. Interestingly, the 312N allele has been found to be less common among men with maldescended testes compared with unaffected controls (Simoni et al., 2008) .
Signaling pathways
LHCGR is capable of binding LH, hCG, and h-hCG, but not hCG free b-subunit (Cole, 2009 (Cole, , 2010 . Nicked hCG binds LHCGR, but with a substantially lower affinity (Cole et al., 1991) . Experiments using hCG and ovine LH indicate that binding of these hormones to LHCGR differentially influences receptor interaction with plasma membrane proteins (Roess et al., 1997) , which may contribute to the subsequent divergence in signaling pathway activation. The intricacies of LHCGR signaling are a subject of active investigation, with many components and interfaces not yet defined. It is generally understood that the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway is a significant effector of downstream events that lead to ovulation and steroid biosynthesis.
The effects of gonadotropin binding appear to be regulated by both temporal and spatial control of cAMP-mediated signaling (Weedon-Fekjaer and Tasken, 2012) . This cascade begins when LHCGR binds LH or hCG. This induces a conformational change in LHCGR, leading to the activation of the stimulatory G-protein G s (Puett et al., 2007) . G s , in turn, activates adenylate cyclase, which increases the intracellular pool of cAMP.
Acting through an independent mechanism, LHCGR stimulation also activates the phospholipase C/inositol phosphate (PLC/IP) signaling pathway (Gilchrist et al., 1996) . Given the high levels of LH or hCG required to activate PLC via LHCGR, it has been suggested that PLC-based signaling only occurs during the pre-ovulatory LH surge and during pregnancy (Gudermann et al., 1992) . Consistent with this role, investigators have recently identified PLC as a mediator of final granulosa cell differentiation in response to LH (Donadeu et al., 2011) .
Other signaling molecules/pathways including extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) and AKT have been identified as major downstream players in LHCGR-mediated signaling, with putative roles in cell proliferation, differentiation, and survival (Ben-Ami et al., 2009; Noma et al., 2011; Palaniappan and Menon, 2010; Shiraishi and Ascoli, 2007) . Together with cAMP/ PKA, the ERK1/2, and AKT pathways contribute to the regulation of oocyte and follicle maturation (Brown et al., 2010; Reizel et al., 2010) .
Although both hLH and hCG bind to LHCGR, emerging evidence suggests that the downstream effects differ. Much like LH and hCG were considered to be functionally equivalent, the result of receptor binding was traditionally presumed to be alike. New data, however, suggest that this is not true. Advances in gonadotropin purification and recombinant technology have allowed investigators to explore hormone-specific signaling cascades, with thought-provoking results.
Casarini and colleagues performed a series of experiments examining changes in gene and protein expression/activation in response to recombinant hLH (r-hLH) or recombinant hCG (r-hCG) exposure in COS-7 cells constitutively expressing LHCGR (COS-7/LHCGR) and in human granulosa cells (hGLC) (Casarini et al., 2012) . Recombinant hCG was found to be five times more potent than hLH with respect to cAMP production, with a commensurate lower ED 50 (Table 3) . cAMP concentration reached its maximum more quickly with r-hLH than with r-hCG in COS-7/ LHCGR cells (10 minutes and 1 hour, respectively). During extended gonadotropin exposure in hGLC cells, in which LHCGR expression was physiologically regulated, cAMP levels cycled, with a period of approximately 4-5 h (Fig. 2) . Interestingly, extracellular cAMP levels were not cyclical. Peak intracellular cAMP levels were generally higher with r-hCG than with r-hLH. Nonetheless, progesterone production was similar, with supernatant concentrations continuing to increase throughout the 36-hour evaluation period. In addition, recombinant hLH stimulation of hGLC cells strongly activated ERK1/2 and AKT, but hCG only weakly affected these pathways (Table 3) . Blockage of the ERK1/2 and/or AKT pathways influenced downstream gene expression in hGLC exposed to r-hLH but not those stimulated with r-hCG. To exclude the possibility that these findings were specific to recombinant gonadotropins that do not undergo post-translational modification of native proteins, the authors repeated the dose-response experiments using extractive hLH and hCG, with results comparable to that of r-hLH and r-hCG.
Disparate effects on signaling between LH and hCG also have been described in goat ovarian granulosa cells (Gupta et al., 2012) . In this model, sustained exposure in cell culture led to significantly greater cAMP accumulation with hCG vs. ovine LH (p < 0.05). Long-term culture in the presence of LH supported growth and proliferation of granulosa cells; hCG, on the other Fig. 3 . Theoretical pathways for the divergence in receptor-mediated signaling between luteinizing hormone (LH) and human chorionic gonadotropin (hCG). Although acting on the same receptor, accumulating evidence suggests that LH binding (A) has a greater impact (thicker arrow) on AKT and extracellular signalregulated protein kinase (ERK1/2) phosphorylation than hCG does, whereas binding of hCG (B) generates a greater intracellular accumulation (thicker arrow) of cAMP than does LH (Casarini et al., 2012; Gupta et al., 2012) . Pathway components derived from Arey and Lopez (2011) . AC, adenylate cyclase; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; Gs/Gq, G proteins; IP3, inositol triphosphate; LHCGR, luteinizing hormone/choriogonadotropin receptor; PKA, protein kinase A; PLC, phospholipase C; PKC, protein kinase C. hand, had the opposite effect, slowing growth and increasing cell doubling time. Consistent with the previously described experiments using human granulosa cells, phospho-ERK1/2 levels were greater after long-term exposure to LH compared with hCG.
Using the aforementioned data in combination with known elements of LHCGR signaling, we have constructed a schematic illustrating potential differences between LH-and hCG-mediated signaling pathways (Fig. 3) . This diagram is an acknowledged simplification of the complex interactions between diverse cascades that coordinately regulate gonadotropin response. Further exploration in different cell types and physiologic conditions is needed to fully characterize the unique aspects of signaling via LH or hCG.
Extragonadal LHCGR
Detection of LHCGR in regions other than ovarian cell types and Leydig cells of the testes, including the decidua, uterine vasculature, umbilical cord, fetal organs, cytotrophoblast cells, and adrenal cortex, has spurred ongoing debate regarding the potential role for gonadotropins in extragonadal locations (Cole, 2010; Pakarainen et al., 2007; Rao, 2010) . It has been suggested that the absence of overt non-gonadal phenotypes in individuals with naturally occurring LHCGR mutations indicates that LH and hCG have only modest effects on the normal physiologic activity of these tissues (Ascoli et al., 2002) . Moreover, the extragonadal phenotypes in LHCGRknockout and hCG overexpressing mice have been attributed chiefly to changes in gonadal function rather than a physiologic role for LHCGR in non-gonadal tissue (Pakarainen et al., 2007; Rahman and Rao, 2009 ). It should be noted, however, that CG is not a native constituent of the mouse genome; yet it is hCG for which the strongest evidence of extragonadal activity has been unearthed.
As previously discussed, the enduring presence of hCG beyond the time period associated with luteal support implies additional functionality. hCG is implicated in multiple modes of supporting pregnancy in addition to promoting progesterone production. Implantation, trophoblast invasion, placentation, uterine growth control, growth and differentiation of fetal organs, as well as a host of other putative or known functions of hCG that are listed in Table 2 (Banerjee and Fazleabas, 2011; Cole, 2010) . While it seems clear that extragonadal LHCGR has functional significance, further study is needed to clarify its role in normal and aberrant cellular processes and to characterize the individual effects of various isoforms.
Conclusions
The significance of differences between LH and hCG in terms of structure, expression, regulation, and function is just beginning to be fully realized. It has long been known that LH and hCG fundamentally differ in their expression patterns; however, we now appreciate that categorization based on this attribute alone fails to adequately describe the complexity and unique aspects of these hormones. Moreover, an array of isoforms exists within a single hormone family, the composition of which fluctuates during the course of the ovarian cycle and pregnancy as well as throughout the lifespan in both men and women. Emerging evidence suggests that these diverse isoforms have distinct, though often overlapping, functions that are reflected by their relative abundance in normal and aberrant physiologic processes. The importance of quantitative and qualitative distinctions in signaling cascades activated by LH and hCG and the clinical relevance of extragonadal activity are nascent areas of study that merit further exploration. All of these advances in knowledge broaden the ability to utilize LH and hCG as diagnostic and prognostic biomarkers, as well as therapeutic tools to help manage clinical conditions such as infertility.
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